Earnings Watch: AMD, Novo Nordisk, and Apple Earnings Watch: AMD, Novo Nordisk, and Apple Earnings Watch: AMD, Novo Nordisk, and Apple

Earnings Watch: AMD, Novo Nordisk, and Apple

Peter Garnry

Head of Equity Strategy

Summary:  The Q1 earnings season has been better than feared showing companies that are still confident about the outlook and the technology sector is showing so far that operating income is growing again following significant cost-cutting. In this week's earnings we focus on AMD, Novo Nordisk, and Apple where all three companies face quite steep expectations from investors following strong share price performances this year.

Technology is back in growth mode

The significant amount of cost-cutting among technology companies is beginning to yield results for technology companies with Nasdaq 100 expanding EBITDA in Q1 q/q while both the S&P 500 and the STOXX 600 are so far reporting declines in EBITDA q/q. Another key observation is that European companies continue to do well relative to US companies underpinning the case for European equities this year. The US companies are always leading the earnings season so these conclusions may change before the season is over and this week’s results from AMD and Apple could change the positive turnaround in operating income that we are observing so far in the Nasdaq 100. While US equities have come back recently, the main risk and issue with US equities remain the high equity valuation relative to other equity markets and with a 12-month 12.8x EV/EBITDA the US equity market comes with a significant valuation premium to global equities.

Another busy earnings week with focus on AMD, Novo Nordisk, and Apple

The three stocks we are focusing on for this week’s earnings releases are AMD, Novo Nordisk, and Apple because there are all popular companies, with strong growth record, and important for their respective industries.

Will AMD continue to ride the AI hype?

AMD reports Q1 earnings tomorrow after the US market close with analysts expecting revenue of $5.3bn down 10% y/y and EBITDA of $1.27bn down from $1.71bn a year ago reflecting increased input costs and lower demand as corporate technology spending is declining and gaming is not as hot as during the pandemic. With expectations set low for Q1 we expect AMD to clear this bar easily, but expectations are certainly steeper for the coming quarters as the AI hype with ChatGPT has lifted AMD’s share price 38% this year and thus the Q2 guidance will be key for the market’s reaction.

Novo Nordisk is up against extreme expectations

Novo Nordisk reports Q1 earnings on Thursday before the market opens in Copenhagen with analysts expecting Q1 revenue of DKK 51.8bn up 23% y/y and EBITDA of DKK 25bn up from DKK 20.8bn a year ago driven by strong growth in the company’s weight loss drug Wegovy. Back in early February we wrote a game changer equity note on Novo Nordisk with a special focus on Wegovy as the company’s next important growth driver. Novo Nordisk has got a head start on this new class of weight loss drugs with Eli Lilly waiting for its FDA approval and the market is really excited about the growth outlook sending Novo Nordisk shares up 21% this year.

Can Apple get back to above average growth?

Apple reports FY23 Q2 earnings (ending 31 March) on Thursday after the market close with analysts expecting revenue of $92.6bn down 5% y/y and EBITDA of $30.2bn down from $32.7bn a year ago as input costs remain hot demand has been negatively impacted by high inflation in key markets reducing consumers appetite for Apple’s pricier electronic devices such as the iPhone. We expect Apple to guide weak Mac sales and the risk has gone up that iPhone guidance could disappoint as well. With the share price up 31% this year expectations might be too high for even Apple.

AMD, Novo Nordisk, and Apple weekly total return the past five years | Source: Bloomberg

The list below shows all the most important earnings releases to watch this week with especially Thursday being the main course with key earnings from Shopify on e-commerce, Maersk on logistics, Volkswagen and BMW on EV growth, Infineon on semiconductor pick-up, Rheinmetall on EU military spending, Zalando on EU consumer spending, Shell on energy markets, ArcelorMittal on steel demand, Booking on travel, Ferrari on luxury, and lastly Fortinet on cyber security.

  • Monday: Berkshire Hathaway, Stryker, Vertex Pharmaceuticals, NXP Semiconductors

  • Tuesday: Thomson Reuters, HSBC, BP, DBS Group, Geberit, Pfizer, AMD, Starbucks, Uber Technologies, Marathon Petroleum, Ford Motor

  • Wednesday: Barrick Gold, Orsted, Airbus, BNP Paribas, Deutsche Post, Enel, UniCredit, Lloyds Banking Group, Qualcomm, CVS Health, Estee Lauder, MercadoLibre, Kraft Heinz

  • Thursday: National Australia Bank, Anheuser-Busch InBev, Shopify, Novo Nordisk, Maersk, Volkswagen, BMW, Infineon Technologies, Uniper, Rheinmetall, Zalando, Shell, ArcelorMittal, Equinor, Apple, ConocoPhillips, Booking, Regeneron Pharmaceuticals, Zoetis, Becton Dickinson, EOG Resources, Ferrari, Fortinet

  • Friday: ANZ, Macquire Group, Enbridge, Canadian Natural Resources, Adidas, Intesa Sanpaolo, CaixaBank, Cigna Group

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000

Contact Saxo

Select region


The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.